Institutional members access full text with Ovid®

Share this article on:

Multiple Sclerosis Drug Fingolimod Receives New Safety Warnings Related to Cardiovascular Risk

Aschenbrenner, Diane S. MS, RN

AJN The American Journal of Nursing: September 2012 - Volume 112 - Issue 9 - p 23,24
doi: 10.1097/01.NAJ.0000418919.07483.75
Drug Watch
  • Fingolimod (Gilenya), a drug used in the treatment of relapsing forms of multiple sclerosis, has new labeled warnings related to the potential for serious and potentially life-threatening bradycardia.
  • The risk of bradycardia is heightened in the first six hours after the initial dose, as well as between 12 and 20 hours after the first dose.

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch:

© 2012 Lippincott Williams & Wilkins, Inc.